Symbio Pharmaceuticals Limited (JP:4582)
:4582
Want to see JP:4582 full AI Analyst Report?
Top Page
Symbio Pharmaceuticals Limited
(4582)
Select Model
Select Model
Rating:41Neutral
Price Target:
¥67.00
▼(-25.56% Downside)
Action:Reiterated
Date:05/15/26
The score is driven primarily by weakened financial performance (multi-year losses, heavy cash burn, and rising leverage with shrinking equity). Technicals also detract due to a clear downtrend and weak momentum. Valuation provides limited support because a negative P/E reflects ongoing losses and no dividend yield is available.
Positive Factors
High gross margin
Sustainably high gross margins indicate favorable product economics and pricing power in specialty medicines. Over a 2–6 month horizon this cushion supports margin recovery if operating costs stabilize, enabling faster path back to profitability once revenues or efficiency improve.
Negative Factors
Sharp revenue decline & multi-year losses
Sustained revenue declines and multi-year operating losses materially weaken the company's ability to fund development and commercialization internally. Over months this reduces strategic optionality, pressures working capital, and lengthens time to achieve break-even absent external support or a clear revenue turnaround.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margin
Sustainably high gross margins indicate favorable product economics and pricing power in specialty medicines. Over a 2–6 month horizon this cushion supports margin recovery if operating costs stabilize, enabling faster path back to profitability once revenues or efficiency improve.
Read all positive factors
Symbio Pharmaceuticals Limited (4582) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥5.34B
Dividend YieldN/A
Average Volume (3M)577.10K
Price to Earnings (P/E)―
Beta (1Y)0.81
Revenue Growth-39.73%
EPS Growth-9.00%
CountryJP
Employees108
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-100.12
Shares Outstanding76,352,486
10 Day Avg. Volume434,010
30 Day Avg. Volume577,100
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)3.55
Price to Sales (P/S)3.46
P/FCF Ratio-0.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Symbio Pharmaceuticals Limited Business Overview & Revenue Model
Company Description
SymBio Pharmaceuticals Limited, established in 2005 and headquartered in Tokyo, Japan, is a pharmaceutical company focused on the research, development, production, and commercialization of medicinal products, primarily within the oncology and hem...
How the Company Makes Money
Symbio Pharmaceuticals generates revenue primarily from the sale of its pharmaceutical products in Japan once they are approved and launched. In addition, the company’s business model commonly involves licensing arrangements: it in-licenses drug r...
Symbio Pharmaceuticals Limited Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
44
Neutral
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.82B | 1.31B | 2.45B | 5.59B | 10.01B | 8.25B |
| Gross Profit | 1.37B | 947.34M | 1.87B | 4.41B | 7.60B | 5.80B |
| EBITDA | -4.61B | -4.60B | -3.78B | -714.00M | 2.06B | 1.11B |
| Net Income | -4.66B | -4.78B | -3.83B | -1.96B | 1.18B | 2.03B |
Balance Sheet | ||||||
| Total Assets | 4.14B | 3.87B | 4.97B | 8.17B | 17.43B | 15.18B |
| Cash, Cash Equivalents and Short-Term Investments | 3.05B | 2.88B | 3.96B | 6.52B | 6.28B | 3.86B |
| Total Debt | 1.30B | 1.98B | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 1.78B | 2.60B | 770.77M | 8.14B | 8.92B | 8.43B |
| Stockholders Equity | 2.36B | 1.27B | 4.20B | 7.21B | 8.51B | 6.75B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -4.58B | -3.44B | -427.48M | 1.57B | 76.20M |
| Operating Cash Flow | 0.00 | -4.58B | -3.42B | -194.69M | 1.61B | 140.04M |
| Investing Cash Flow | 0.00 | -75.92M | -3.96M | -376.70M | -47.13M | -70.85M |
| Financing Cash Flow | 0.00 | 3.62B | 708.47M | 680.16M | 627.99M | -71.92M |
Symbio Pharmaceuticals Limited Technical Analysis
Negative
90.00
Price Trends
88.90
Negative
100.40
Negative
110.13
Negative
Market Momentum
-5.49
Negative
26.58
Positive
24.57
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4582, the sentiment is Negative. The current price of 90 is above the 20-day moving average (MA) of 76.60, above the 50-day MA of 88.90, and below the 200-day MA of 110.13, indicating a bearish trend. The MACD of -5.49 indicates Negative momentum. The RSI at 26.58 is Positive, neither overbought nor oversold. The STOCH value of 24.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4582.
Symbio Pharmaceuticals Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ¥12.67B | 23.72 | ― | ― | 1.62% | -25.43% | |
53 Neutral | ¥8.47B | 37.27 | ― | 1.06% | 27.18% | 252.59% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥5.52B | 27.79 | ― | 3.21% | 1.60% | -32.76% | |
45 Neutral | ¥3.27B | -4.37 | ― | ― | -49.42% | 44.10% | |
42 Neutral | ¥6.28B | -6.93 | -90.96% | ― | 24.62% | 60.41% | |
41 Neutral | ¥5.34B | -0.80 | ― | ― | -39.73% | -9.00% |
* Healthcare Sector Average
JP:4582
Symbio Pharmaceuticals Limited
70.00
-104.00
-59.77%
JP:4597
Solasia Pharma KK
23.00
-7.00
-23.33%
JP:4512
Wakamoto Pharmaceutical Co., Ltd.
244.00
-58.45
-19.33%
JP:4539
Nippon Chemiphar Co., Ltd.
1,528.00
90.87
6.32%
JP:4574
Taiko Pharmaceutical Co., Ltd.
253.00
5.00
2.02%
JP:4586
Medrx Co., Ltd.
55.00
-6.00
-9.84%
Symbio Pharmaceuticals Limited Corporate Events
SymBio Pharma Swings to Negative Equity as Losses Deepen in Q1 2026
May 7, 2026
SymBio Pharmaceuticals reported first-quarter 2026 consolidated net sales of ¥233 million, down 11.6% year on year, alongside an operating loss of ¥2,341 million and a net loss attributable to owners of the parent of ¥2,401 million....
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.